ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY

摘要

Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.